Lv52
1440 积分 2024-09-18 加入
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
17天前
已完结
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
1个月前
已完结
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
1个月前
已完结
HSP90 buffers deleterious genetic variations in BRCA1
2个月前
已关闭
Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer
2个月前
已关闭
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2个月前
已完结
Exploring ribosome biogenesis in lung adenocarcinoma to advance prognostic methods and immunotherapy strategies
3个月前
已完结
Development and Validation of Palmitoylation-Related Genes in the Prognostic and Immunologic Characterization of Lung Adenocarcinoma
3个月前
已关闭
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
4个月前
已完结
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer
5个月前
已完结
皖公网安备34019202002308
